Tracheobronchial Drug Exposure Should Not Be Confused with Parenchymal Target Achievement for Nebulized Amikacin
-
By
-
Guofu Mao
-
Haizhen Lan
-
April 29, 2026
-
0 min
Tracheobronchial Drug Exposure Should Not Be Confused with Parenchymal Target Achievement for Nebulized Amikacin
Overview
This report emphasizes the distinction between tracheobronchial drug exposure and parenchymal target achievement in the context of nebulized amikacin. It highlights that while tracheobronchial delivery is effective for preventing ventilator-associated pneumonia, it may not suffice for treating established pneumonia.
Background
Understanding the pharmacokinetics of nebulized amikacin is crucial for optimizing treatment strategies in intubated patients. The distinction between tracheobronchial and parenchymal targets is essential for guiding clinical decisions, particularly in the prevention versus treatment of pneumonia. This differentiation can help reconcile conflicting findings in existing literature regarding the efficacy of inhaled antibiotics.
Data Highlights
No numerical data available in the source material.
Key Findings
['Tracheobronchial drug exposure is relevant for proximal airway decontamination.', 'Inhaled amikacin reduced ventilator-associated pneumonia incidence in the AMIKINHAL trial.', 'The INHALE trial did not support the use of inhaled amikacin for established Gram-negative pneumonia.', 'Adjunctive inhaled amikacin improved bacterial eradication in proximal airways but not in pulmonary tissue.', 'Future studies should differentiate between prophylactic and treatment strategies for inhaled antibiotics.']Clinical Implications
Clinicians should consider the specific therapeutic goals when using nebulized amikacin, recognizing that airway exposure may not equate to effective treatment of pneumonia. Future trial designs should focus on relevant pharmacokinetic endpoints that reflect the clinical objectives.
Conclusion
The distinction between tracheobronchial and parenchymal drug exposure is critical for optimizing the use of nebulized amikacin in clinical practice. Understanding this difference can enhance treatment strategies and improve patient outcomes.
References
- Gregoire et al., Critical Care, 2023 -- Amikacin pharmacokinetics after nebulization among intubated patients
- Inhaled amikacin adjunctive to intravenous standard-of-care antibiotics in mechanically ventilated patients with Gram-negative pneumonia (INHALE): a double-blind, randomised, placebo-controlled, phase 3, superiority trial - PubMed
- Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society
- Surgical Endoscopy — A multi-nozzle nebulizer fails to enhance drug delivery to tissues during PIPAC
- Open Forum Infectious Diseases — Impact of Amikacin Liposome Inhalation Suspension on Amikacin Resistance in Patients with Persistent Mycobacterium avium Complex Pulmonary Disease
- Drugs - Real World Outcomes — Evaluating Readmission Rates in Patients with Chronic Obstructive Pulmonary Disease: A Comparison of Nebulized Long-Acting β2-Agonists
- Intensive Care Medicine — Highlights from Intensive Care Medicine 2012: Focus on Pneumonia, Infections, Sepsis, Coagulation, Hemodynamics, Cardiovascular Issues, Microcirculation, Critical Care Management, Imaging Techniques, and Ethical Considerations
- Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society
- Inhaled amikacin adjunctive to intravenous standard-of-care antibiotics in mechanically ventilated patients with Gram-negative pneumonia (INHALE): a double-blind, randomised, placebo-controlled, phase 3, superiority trial - PubMed
- Amikacin pharmacokinetics after nebulization among intubated patients | Critical Care | Springer Nature Link
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
